ClinicalTrials.gg
Active, not recruitingNCT07038369Updated Aug 7, 2026

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Phase 1 interventional study of ATV-1601 and ATV-1601 + Fulvestrant in Advanced Solid Tumors, Breast Cancer and Breast Carcinoma, sponsored by Atavistik Bio, Inc. Active, not recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Atavistik Bio, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 162 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
162nd of 605
134 · median 52
Started
2025
with 46 others
Phase 1
246 of 645
52 open now
Primary completion
2028-08
later than 194 of 263 live
Registered
593rd of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 162nd largest by planned enrollment of the 605 interventional ones that give a count, is one of 47 that started in 2025, is one of 246 in phase 1, reaches primary completion later than 194 of the 263 other live ones, and was the 593rd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

162 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.

Read the detailed description

This is a first-in-human, open-label, multicenter, Phase 1a/1b dose escalation dose finding, and dose expansion study to evaluate safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of ATV-1601 as monotherapy in participants with advanced or metastatic solid tumors with the AKT1 E17K mutation, and in combination with fulvestrant in participants with breast cancer that has the AKT1 E17K mutation. This study has a dose escalation and expansion phase with ATV-1601, and an escalation and expansion phase in combination with Fulvestrant.

03

Conditions studied

  • Advanced Solid Tumors
  • Breast Cancer
  • Breast Carcinoma
  • Breast Neoplasms
  • ER Positive Breast Cancer
  • Cervical Cancers
  • Cervical Neoplasms
  • Cervical Carcinoma
  • Triple Negative Breast Cancer
  • Gynecologic Cancers
  • Gynecologic Neoplasm
  • Endometrial Cancer
  • Endometrial Neoplasm
  • Endometrial Carcinoma (EC)
  • Fallopian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Prostate Cancers
  • Prostate Carcinoma
  • Solid Tumors
  • Neoplasms
  • Neoplasms by Site
  • Breast Diseases
  • Uterine Neoplasms
  • Genital Neoplasms, Female
  • Urogenital Neoplasms

Keywords

  • AKT mutation
  • Mutant AKT
  • AKT1 mutation
  • AKT mutant
  • Gynecologic carcinoma
  • Fallopian Carcinoma
  • Fallopian Neoplasm
  • HR positive breast
  • AKT Gene Mutation
  • AKT1 E17K
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 444 are open to participants now.

This study's planned enrollment of 134 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Atavistik Bio, Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed or advanced-stage solid malignant tumor or HR+/- breast cancer.
  2. Have progressed on, were intolerant to, or experienced disease recurrence after standard therapy and have no available effective or tolerable treatment options to derive benefit.
  3. Tumor must have documented specific mutation profile as outlined below based on local laboratory testing.
  4. Participants with solid tumors or HR+/HER2- breast cancer with AKT1 E17K mutations.
  5. according to v1.1 criteria.
  6. Formalin-fixed paraffin-embedded tumor specimen available for submission.
  7. performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. Previously documented activating mutations in KRAS, NRAS, HRAS, or BRAF.
  2. Inadequate bone marrow reserve or organ function.
  3. abnormalities of glucose metabolism.
  4. Participants who are symptomatic or have uncontrolled .
  5. Requires treatment with certain medications.

Participants must meet other inclusion/exclusion criteria.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Experimental/Part 1a: ATV-1601

    ATV-1601

    Drug: ATV-1601

  • Experimental
    Experimental/Part 1b: ATV-1601 + Fulvestrant

    ATV-1601 + Fulvestrant

    Combination Product: ATV-1601 + Fulvestrant

Interventions

  • DrugATV-1601

    Drug: ATV-1601 • Oral ATV-1601

  • Combination productATV-1601 + Fulvestrant

    Drug page: Fulvestrant

    Drug: ATV-1601 * Oral ATV-1601 Drug: Fulvestrant * Intramuscular Injection

07

What researchers measure

Primary outcomes

  1. Expansion: Maximum and minimum plasma concentration

    Drug concentration in Blood.

    Time frame: Approximately 48 months.

  2. Expansion: Time to C Max

    Drug concentration in Blood

    Time frame: Approximately 48 months

  3. Expansion: Area under the concentration-time curve

    Drug concentration in Blood

    Time frame: Approximately 48 months

  4. Expansion: AUC at end of dosing interval

    Drug concentration in Blood

    Time frame: Approximately 48 months

  5. Expansion: AUC extrapolated to infinity

    Drug concentration in Blood

    Time frame: Approximately 48 months

  6. Expansion: Half-life

    Drug concentration in Blood

    Time frame: Approximately 48 months

  7. Expansion: Trough Concentrations

    Drug concentration in Blood

    Time frame: Approximately 48 months

  8. Escalation & Expansion: Safety and Tolerability of monotherapy.

    Number of participants with Treatment Emergent Adverse Events (TEAEs). Safety will be assessed by monitoring adverse events, laboratory tests and ECG results.

    Time frame: Approximately 48 months.

  9. Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 in monotherapy.

    Number of patients with dose-limiting toxicities.

    Time frame: Approximately 48 months.

  10. Escalation: Maximum tolerated dose and/or recommended phase 2 dose of ATV-1601 combination with fulvestrant.

    Number of patients with dose-limiting toxicities.

    Time frame: Approximately 48 months.

Secondary outcomes

  1. Escalation: Maximum and minimum plasma concentration

    Drug concentration in Blood.

    Time frame: Approximately 48 months.

  2. Escalation: Time to C max

    Drug concentration in Blood

    Time frame: Approximately 48 months

  3. Escalation: Area under the concentration-time curve

    Drug concentration in Blood

    Time frame: Approximately 48 months

  4. Escalation: AUC at end of dosing interval

    Drug concentration in Blood

    Time frame: Approximately 48 months

  5. Escalation: AUC extrapolated to infinity

    Drug concentration in Blood

    Time frame: Approximately 48 months

  6. Escalation: Half-life

    Drug concentration in Blood

    Time frame: Approximately 48 months

  7. Escalation: Trough Concentrations

    Drug concentration in Blood

    Time frame: Approximately 48 months

  8. Escalation & Expansion: Objective response rate

    Tumor measurements by RECIST 1.1

    Time frame: Approximately 48 months

  9. Escalation & Expansion: Duration of Response

    Tumor measurements by RECIST 1.1

    Time frame: Approximately 48 months

  10. Escalation & Expansion: Clinical Benefit Rate

    Tumor measurements by RECIST 1.1

    Time frame: Approximately 48 months

  11. Expansion: Progression Free Survival

    Tumor measurements by RECIST 1.1

    Time frame: Approximately 48 months

08

Study locations

8 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2028, 37 months after the start.

Of 136 industry-sponsored phase 1 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 70. This study's planned 37 months is below that.

Counting every sponsor, half of 209 studies reached it within 54 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038369
Lead sponsor
Atavistik Bio, Inc
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jul 29, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Aug 7, 2026

Study contacts

Study Director
study director · Atavistik Bio

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion